Project description DEENESFRITPL Novel drug combination treatment for tuberculosis Tuberculosis (TB) is still the world's most deadly infectious disease, and multidrug-resistant TB poses a serious threat to global health. Treatment options are limited and often associated with many adverse effects from the drugs. The overall objective of the EU-funded RespiriTB project is to find new drug candidates for efficient combination treatment against TB and multidrug-resistant TB. The drug combination will target the energy metabolism of Mycobacterium tuberculosis (Mtb), using recently discovered inhibitors of the Mtb respiratory pathway. It will also target host factors that are essential for the intracellular survival of Mtb. The project presents a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce incidences of drug resistance. Show the project objective Hide the project objective Objective Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Thus, there is an acute need for the development of a novel combination regimen with an indication for effective, shorter, and safer treatment of all forms of TB. The overall objective of RESPIRI-TB is to find new drug candidates as potential components of a new, more efficient combination drug regimen against TB that is less prone to resistance and allows shortening of treatment duration for TB, and multidrug-resistant TB. Such a drug combination will synergistically target the energy metabolism of Mtb or complementary targets. To achieve this, we will advance recently discovered inhibitors of the Mtb respiratory pathway. In addition, we will target the Mtb specific molecular mechanism that reduces reactive oxygen species in the cell. Finally, we will also target host-factors that are essential for the intracellular survival of Mtb. Together, we present a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce chances of drug resistance. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesclinical medicinepneumologytuberculosismedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2) Topic(s) IMI2-2018-16-01 - Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors Call for proposal H2020-JTI-IMI2-2018-16-single-stage See other projects for this call Funding Scheme RIA - Research and Innovation action Coordinator ACADEMISCH ZIEKENHUIS LEIDEN Net EU contribution € 968 282,50 Address ALBINUSDREEF 2 2333 ZA Leiden Netherlands See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 499 301,50 Participants (8) Sort alphabetically Sort by Net EU contribution Expand all Collapse all UNIVERSITEIT LEIDEN Netherlands Net EU contribution € 124 375,00 Address RAPENBURG 70 2311 EZ Leiden See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 124 375,00 UNIVERSITEIT ANTWERPEN Belgium Net EU contribution € 4 179 723,34 Address PRINSSTRAAT 13 2000 Antwerpen See on map Region Vlaams Gewest Prov. Antwerpen Arr. Antwerpen Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 4 179 723,34 SORBONNE UNIVERSITE France Net EU contribution € 343 875,00 Address 21 RUE DE L'ECOLE DE MEDECINE 75006 Paris See on map Region Ile-de-France Ile-de-France Paris Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 638 375,00 MEDIZINISCHE UNIVERSITAET WIEN Austria Net EU contribution € 813 125,00 Address SPITALGASSE 23 1090 Wien See on map Region Ostösterreich Wien Wien Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 813 125,00 KOBENHAVNS UNIVERSITET Denmark Net EU contribution € 99 638,53 Address NORREGADE 10 1165 Kobenhavn See on map Region Danmark Hovedstaden Byen København Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 99 638,53 JANSSEN PHARMACEUTICA NV Belgium Net EU contribution € 0,00 Address TURNHOUTSEWEG 30 2340 Beerse See on map Region Vlaams Gewest Prov. Antwerpen Arr. Turnhout Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 297 381,00 MITOLOGICS France Net EU contribution € 146 630,63 Address AVENUE GASTON ROUSSEL 102 93230 Romainville See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ile-de-France Ile-de-France Seine-Saint-Denis Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 146 630,63 FFUND BV Netherlands Net EU contribution € 164 350,00 Address HOLLANDSE KADE 32 1391 JM Abcoude See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region West-Nederland Utrecht Utrecht Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 164 350,00
